Patents Assigned to Acceleron Pharma Inc.
  • METHODS FOR INCREASING THERMOGENIC ADIPOCYTES
    Publication number: 20140328845
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Noda1, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Application
    Filed: April 1, 2014
    Publication date: November 6, 2014
    Applicant: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • ISOLATED NUCLEOTIDE SEQUENCES ENCODING GDF TRAPS
    Publication number: 20140314759
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: March 7, 2014
    Publication date: October 23, 2014
    Applicant: ACCELERON PHARMA, INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • ANTAGONISTS OF BMP9, BMP10, ALK1 AND OTHER ALK1 LIGANDS, AND USES THEREOF
    Publication number: 20140227254
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
    Type: Application
    Filed: December 27, 2013
    Publication date: August 14, 2014
    Applicant: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Robert S. Pearsall, Asya Grinberg, Ravindra Kumar
  • Uses of Cerberus and derivatives thereof
    Patent number: 8796199
    Abstract: The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: August 5, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Ravindra Kumar, Jasbir Seehra
  • METHODS OF PROMOTING FAT LOSS COMPRISING ADMINISTERING AN ALK7 INHIBITOR
    Publication number: 20140205600
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Application
    Filed: January 24, 2014
    Publication date: July 24, 2014
    Applicant: ACCELERON PHARMA INC.
    Inventors: John Knopf, Jasbir Seehra
  • ACTRIIA BINDING AGENTS AND USES THEREOF
    Publication number: 20140199317
    Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same.
    Type: Application
    Filed: January 24, 2014
    Publication date: July 17, 2014
    Applicant: ACCELERON PHARMA, INC.
    Inventors: Jasbir Seehra, Erik Martinez-Hackert
  • TREATMENT OF CANCER WITH ALK1 ANTAGONISTS
    Publication number: 20140193425
    Abstract: Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (ALK1) antagonist are provided. Methods for selecting a subject for treatment with an ALK1 antagonist based on the subject being identified as responsive to such treatment are also provided. Some of the diagnostic methods provided herein are based on detecting an ALK1 agonist, e.g., an ALK1 ligand such as BMP9 or BMP10, in a sample obtained from the subject. Diagnostic reagents and kits for determining whether a subject is responsive to treatment with an ALK1 antagonist are also provided.
    Type: Application
    Filed: October 4, 2013
    Publication date: July 10, 2014
    Applicant: Acceleron Pharma, Inc.
    Inventors: John Knopf, Ravindra Kumar, Robert S. Pearsall, Matthew L. Sherman
  • BMP10 propeptides and related methods
    Patent number: 8772234
    Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: July 8, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf
  • Methods for increasing adiponectin
    Patent number: 8765663
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: July 1, 2014
    Assignee: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Ravindra Kumar, Jennifer Lachey, Alan Koncarevic
  • GDF3 propeptides and related methods
    Patent number: 8765670
    Abstract: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: July 1, 2014
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Compositions and methods for increasing serum half-life
    Patent number: 8722615
    Abstract: Provided herein are glycovariant Fc fusion proteins having increased serum half lives. Also provided are methods for increasing the serum half life of an Fc fusion protein by introducing one or more non-endogenous glycosylation sites.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: May 13, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Ravindra Kumar
  • ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
    Patent number: 8710016
    Abstract: In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: April 29, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, Jennifer Lachey
  • Methods for increasing thermogenic adipocytes
    Patent number: 8703694
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF 11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: April 22, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Isolated nucleotide sequences encoding GDF traps
    Patent number: 8703927
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: April 22, 2014
    Assignee: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS
    Publication number: 20140079700
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Application
    Filed: September 16, 2013
    Publication date: March 20, 2014
    Applicant: ACCELERON PHARMA, INC.
    Inventors: John Knopf, Jasbir Seehra
  • Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
    Patent number: 8642031
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: February 4, 2014
    Assignee: Acceleron Pharma, Inc.
    Inventors: Jasbir Seehra, John Knopf, Robert S. Pearsall, Asya Grinberg, Ravindra Kumar
  • Methods of promoting fat loss comprising administering an ALK7 inhibitor
    Patent number: 8637450
    Abstract: The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF-11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 28, 2014
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • Method for promoting bone growth using activin-actriia antagonists
    Patent number: 8629109
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: January 14, 2014
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra
  • ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND USES THEREOF
    Publication number: 20130344067
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
    Type: Application
    Filed: May 31, 2013
    Publication date: December 26, 2013
    Applicant: Acceleron Pharma, Inc.
    Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra
  • ISOLATED GDF TRAP POLYPEPTIDE
    Publication number: 20130244324
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: January 25, 2013
    Publication date: September 19, 2013
    Applicant: ACCELERON PHARMA, INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar